AU2001294060A1 - Chimeric cytoplasmic signalling molecules derived from cd137 - Google Patents

Chimeric cytoplasmic signalling molecules derived from cd137

Info

Publication number
AU2001294060A1
AU2001294060A1 AU2001294060A AU9406001A AU2001294060A1 AU 2001294060 A1 AU2001294060 A1 AU 2001294060A1 AU 2001294060 A AU2001294060 A AU 2001294060A AU 9406001 A AU9406001 A AU 9406001A AU 2001294060 A1 AU2001294060 A1 AU 2001294060A1
Authority
AU
Australia
Prior art keywords
molecules derived
signalling molecules
cytoplasmic signalling
chimeric
chimeric cytoplasmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001294060A
Inventor
Helene Margaret Finney
Alastair David Griffiths Lawson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Celltech Ltd
Original Assignee
Celltech R&D Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celltech R&D Ltd filed Critical Celltech R&D Ltd
Publication of AU2001294060A1 publication Critical patent/AU2001294060A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001294060A 2000-10-16 2001-10-16 Chimeric cytoplasmic signalling molecules derived from cd137 Abandoned AU2001294060A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0025307 2000-10-16
GBGB0025307.0A GB0025307D0 (en) 2000-10-16 2000-10-16 Biological products
PCT/GB2001/004611 WO2002033101A1 (en) 2000-10-16 2001-10-16 Chimeric cytoplasmic signalling molecules derived from cd137

Publications (1)

Publication Number Publication Date
AU2001294060A1 true AU2001294060A1 (en) 2002-04-29

Family

ID=9901363

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001294060A Abandoned AU2001294060A1 (en) 2000-10-16 2001-10-16 Chimeric cytoplasmic signalling molecules derived from cd137

Country Status (6)

Country Link
US (1) US20040038886A1 (en)
EP (1) EP1326987A1 (en)
JP (1) JP2004511246A (en)
AU (1) AU2001294060A1 (en)
GB (1) GB0025307D0 (en)
WO (1) WO2002033101A1 (en)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0225279D0 (en) * 2002-10-30 2002-12-11 Celltech R&D Ltd Biological products
US20130266551A1 (en) 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
WO2006036445A2 (en) 2004-09-24 2006-04-06 Trustees Of Dartmouth College Chimeric nk receptor and methods for treating cancer
KR100729464B1 (en) * 2005-09-06 2007-06-15 주식회사 피에스엠 Mobile type die cleaning apparatus and die cleaning method using plasma
GB0614780D0 (en) 2006-07-25 2006-09-06 Ucb Sa Biological products
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
EP2178896A1 (en) * 2007-07-31 2010-04-28 The Johns Hopkins University Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders
EP2279253B1 (en) 2008-04-09 2016-11-16 Maxcyte, Inc. Engineering and delivery of therapeutic compositions of freshly isolated cells
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
US9273283B2 (en) 2009-10-29 2016-03-01 The Trustees Of Dartmouth College Method of producing T cell receptor-deficient T cells expressing a chimeric receptor
KR20230133410A (en) 2010-12-09 2023-09-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Use of chimeric antigen receptor-modified t cells to treat cancer
EA201391059A1 (en) 2011-01-18 2014-05-30 Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания COMPOSITIONS FOR CANCER TREATMENT AND METHODS OF THEIR APPLICATION
US9833476B2 (en) 2011-08-31 2017-12-05 The Trustees Of Dartmouth College NKP30 receptor targeted therapeutics
EP3326467B1 (en) * 2011-09-16 2020-03-11 Baylor College of Medicine Targeting the tumor microenvironment using manipulated nkt cells
EP3505537A1 (en) 2012-05-07 2019-07-03 Trustees of Dartmouth College Anti-b7-h6 antibody, fusion proteins, and methods of using the same
AU2013204922B2 (en) * 2012-12-20 2015-05-14 Celgene Corporation Chimeric antigen receptors
PL2956175T3 (en) 2013-02-15 2018-05-30 The Regents Of The University Of California Chimeric antigen receptor and methods of use thereof
EP3744736A1 (en) 2013-02-20 2020-12-02 Novartis AG Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
EP3626741A1 (en) 2013-02-20 2020-03-25 The Trustees Of The University Of Pennsylvania Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
JP6493692B2 (en) 2013-03-15 2019-04-10 セルジーン コーポレイション Modified T lymphocytes
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (en) 2013-03-16 2019-03-21 諾華公司 Treatment of cancer with a humanized anti-CD19 chimeric antigen receptor
US10260038B2 (en) 2013-05-10 2019-04-16 Whitehead Institute For Biomedical Research Protein modification of living cells using sortase
CA3225453A1 (en) 2013-12-19 2015-06-25 Novartis Ag Human mesothelin chimeric antigen receptors and uses thereof
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
EP3097117B1 (en) 2014-01-21 2023-10-04 Novartis Ag Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
HUE054588T2 (en) 2014-04-07 2021-09-28 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
EP3943507A1 (en) * 2014-04-10 2022-01-26 Seattle Children's Hospital, dba Seattle Children's Research Institute Drug related transgene expression
CN113604491A (en) 2014-05-02 2021-11-05 宾夕法尼亚大学董事会 Compositions and methods for chimeric autoantibody receptor T cells
CN106459914B (en) 2014-05-15 2020-11-06 新加坡国立大学 Modified natural killer cells and uses thereof
WO2015179833A1 (en) * 2014-05-23 2015-11-26 The Trustees Of The University Of Pennsylvania Compositions and methods for treating antibody resistance
AU2015283704A1 (en) 2014-07-01 2016-12-15 Pfizer Inc. Bispecific heterodimeric diabodies and uses thereof
AU2015292811B2 (en) 2014-07-21 2019-12-19 Novartis Ag Treatment of cancer using a CLL-1 chimeric antigen receptor
TWI750110B (en) 2014-07-21 2021-12-21 瑞士商諾華公司 Treatment of cancer using humanized anti- bcma chimeric antigen receptor
CN112481283A (en) 2014-07-21 2021-03-12 诺华股份有限公司 Treatment of cancer using CD33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
MY189028A (en) 2014-08-19 2022-01-20 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
AU2015317608B2 (en) 2014-09-17 2021-03-11 Novartis Ag Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CA2963935A1 (en) 2014-10-08 2016-04-14 Novartis Ag Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
TW201631152A (en) 2014-12-29 2016-09-01 諾華公司 Methods of making chimeric antigen receptor - expressing cells
US11459390B2 (en) 2015-01-16 2022-10-04 Novartis Ag Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
US10590182B2 (en) 2015-02-24 2020-03-17 The Regents Of The University Of California Binding-triggered transcriptional switches and methods of use thereof
SI3280729T1 (en) 2015-04-08 2022-09-30 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
ES2948133T3 (en) 2015-04-17 2023-08-31 Novartis Ag Methods to improve the efficiency and expansion of cells expressing a chimeric antigen receptor
EP3325504A1 (en) 2015-07-21 2018-05-30 Novartis AG Methods for improving the efficacy and expansion of immune cells
EP3331913A1 (en) 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
CN108780084B (en) 2015-09-03 2022-07-22 诺华股份有限公司 Biomarkers predictive of cytokine release syndrome
EP3393504A1 (en) 2015-12-22 2018-10-31 Novartis AG Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
EP3399991A4 (en) 2016-01-08 2019-08-07 The Regents of The University of California Conditionally active heterodimeric polypeptides and methods of use thereof
EP3432924A1 (en) 2016-03-23 2019-01-30 Novartis AG Cell secreted minibodies and uses thereof
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
TW202340473A (en) 2016-10-07 2023-10-16 瑞士商諾華公司 Treatment of cancer using chimeric antigen receptors
WO2018140725A1 (en) 2017-01-26 2018-08-02 Novartis Ag Cd28 compositions and methods for chimeric antigen receptor therapy
MX2019011272A (en) 2017-03-22 2019-10-24 Novartis Ag Compositions and methods for immunooncology.
BR112019019917A2 (en) 2017-03-27 2020-04-22 Nat Univ Singapore truncated nkg2d chimeric receptors and their uses in natural killer cell immunotherapy
CN110494557A (en) 2017-03-27 2019-11-22 新加坡国立大学 For expanding the stimulation cell line with Activated NK Cells in vitro
WO2018195339A1 (en) 2017-04-19 2018-10-25 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
EP3697436A1 (en) 2017-10-18 2020-08-26 Novartis AG Compositions and methods for selective protein degradation
WO2019136288A1 (en) * 2018-01-05 2019-07-11 Maxcyte, Inc. Chronic car treatment for cancer
KR20210020932A (en) 2018-06-13 2021-02-24 노파르티스 아게 BCMA chimeric antigen receptor and uses thereof
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
IL292924A (en) 2019-11-26 2022-07-01 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6355476B1 (en) * 1988-11-07 2002-03-12 Advanced Research And Technologyinc Nucleic acid encoding MIP-1α Lymphokine
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US7070771B1 (en) * 1996-12-09 2006-07-04 Regents Of The University Of California Methods of expressing chimeric mouse and human CD40 ligand in human CD40+ cells
EP1171596A1 (en) * 1999-04-16 2002-01-16 Celltech Therapeutics Limited Synthetic transmembrane components

Also Published As

Publication number Publication date
WO2002033101A1 (en) 2002-04-25
US20040038886A1 (en) 2004-02-26
EP1326987A1 (en) 2003-07-16
JP2004511246A (en) 2004-04-15
GB0025307D0 (en) 2000-11-29

Similar Documents

Publication Publication Date Title
AU2001294060A1 (en) Chimeric cytoplasmic signalling molecules derived from cd137
AU2001238001A1 (en) Photo-assisted electrolysis
IL161830A (en) 1,2,4-thiadiazolium derivatives as melanocortin receptor modulators
AU2001277262A1 (en) Robust data extension for 8vsb signaling
SI1446394T1 (en) Novel 1,2,4-thiadiazole derivatives as melanocortin receptor modulators
HK1068100A1 (en) Bacillus anthracis exoantigens.
AU2001241733A1 (en) Methods for determining single nucleotide variations
AU4581300A (en) Synthetic signalling molecules
AU2002342866A1 (en) Improved washing system
AU2001241682A1 (en) Gene expression system based on chimeric receptors
AU2002346470A1 (en) Rate selection for an ofdm system
AU2002224085A1 (en) Functional substances derived from oligoolefins having functional groups at the ends
AU2001285740A1 (en) New catalyst system
AU2253100A (en) Compositions obtained from (mangifera indica l.)
AU2002245107A1 (en) Improved biochip
AU2002212445A1 (en) Signalling means
AU2001272351A1 (en) Wiper system
GB9921318D0 (en) Chimeric molecules
AU5552700A (en) Chimeric proteins mediating targeted apoptosis
AU2001288839A1 (en) Self-rearranging dna vectors
HK1059784A1 (en) Sodium channel modulators derived from 2-piperidylimidazoles.
AU7123101A (en) New spinal system
AU2002216625A1 (en) Intracellular signaling molecules
AU2001218019A1 (en) Valved vessel system
AU2001233877A1 (en) Optical signalling system